Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
(NASDAQ: QNRX) Delayed: 3.25 -1.16 (26.3%)
Previous Close $4.41    52 Week High $ 
Open $4.20    52 Week Low $ 
Day High $5.07    P/E N/A 
Day Low $3.25    EPS $ 
Volume 3,496,293